Kymera Therapeutics (KYMR) News Today → Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad) Free KYMR Stock Alerts $33.53 -0.52 (-1.53%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 26 at 4:08 AM | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from HC WainwrightMay 24, 2024 | markets.businessinsider.comDemystifying Kymera Therapeutics: Insights From 5 Analyst ReviewsMay 24, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $46.00 target price on shares of Kymera Therapeutics in a research report on Friday.May 23, 2024 | finance.yahoo.comKymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingMay 23, 2024 | globenewswire.comKymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingMay 23, 2024 | marketbeat.comTrexquant Investment LP Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Trexquant Investment LP acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 203,564 shares of the compaMay 22, 2024 | globenewswire.comKymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual MeetingMay 21, 2024 | americanbankingnews.comReviewing Genus (OTCMKTS:GENSF) & Kymera Therapeutics (NASDAQ:KYMR)May 20, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Trading 4.8% Higher Kymera Therapeutics (NASDAQ:KYMR) Stock Price Up 4.8%May 18, 2024 | americanbankingnews.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of "Moderate Buy" from AnalystsMay 14, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Shares Down 5.5% Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 5.5%May 14, 2024 | globenewswire.comKymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Inhibrx (INBX)May 8, 2024 | globenewswire.comKymera Therapeutics to Participate in Upcoming May Investor ConferencesMay 5, 2024 | finance.yahoo.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkMay 3, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPSKymera Therapeutics (NASDAQ:KYMR - Get Free Report) announced its earnings results on Thursday. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The firm had revenue of $10.30 million for the quarter, compared to the consensus estimate of $14.24 million. During the same period in the previous year, the business earned ($0.70) EPS. The business's quarterly revenue was up 8.4% compared to the same quarter last year.May 3, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Kymera Therapeutics (KYMR)May 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kymera Therapeutics Backed by Promising KT-253 Program Data and Upcoming ASCO Meeting AnticipationMay 3, 2024 | finance.yahoo.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comOppenheimer Trims Kymera Therapeutics (NASDAQ:KYMR) Target Price to $52.00Oppenheimer lowered their price objective on shares of Kymera Therapeutics from $53.00 to $52.00 and set an "outperform" rating on the stock in a research report on Friday.May 3, 2024 | finance.yahoo.comKymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 2, 2024 | investorplace.comKYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024May 2, 2024 | msn.comKymera Therapeutics GAAP EPS of -$0.69 beats by $0.04, revenue of $10.3M misses by $2.75MMay 2, 2024 | globenewswire.comKymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateMay 1, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Trading Up 6.8%Kymera Therapeutics (NASDAQ:KYMR) Trading Up 6.8%May 1, 2024 | markets.businessinsider.comKymera Therapeutics earnings preview: what Wall Street is expectingMay 1, 2024 | msn.comKymera Therapeutics Q1 2024 Earnings PreviewApril 26, 2024 | marketbeat.comKymera Therapeutics (KYMR) Scheduled to Post Quarterly Earnings on ThursdayKymera Therapeutics (NASDAQ:KYMR) will be releasing earnings before the market opens on Thursday, May 2, Zacks reports.April 25, 2024 | globenewswire.comKymera Therapeutics to Report First Quarter 2024 Financial Results on May 2April 24, 2024 | investing.comKymera Therapeutics stock gets Outperform rating on positive outlookApril 24, 2024 | nasdaq.comCommit To Buy Kymera Therapeutics At $17.50, Earn 9% Annualized Using OptionsApril 23, 2024 | msn.comOppenheimer Initiates Coverage of Kymera Therapeutics (KYMR) with Outperform RecommendationApril 22, 2024 | benzinga.comKymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)April 22, 2024 | marketbeat.comOppenheimer Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)Oppenheimer initiated coverage on shares of Kymera Therapeutics in a research note on Monday. They issued an "outperform" rating and a $53.00 target price for the company.April 18, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Price Up 4.5%Kymera Therapeutics (NASDAQ:KYMR) Trading 4.5% HigherApril 15, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Growth in Short InterestKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 9,060,000 shares, an increase of 8.8% from the March 15th total of 8,330,000 shares. Based on an average daily trading volume, of 752,000 shares, the days-to-cover ratio is presently 12.0 days.April 11, 2024 | marketbeat.comResearch Analysts Offer Predictions for Kymera Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:KYMR)Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Brookline Capital Management boosted their Q1 2024 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a research note issued on Monday, April 8th. Brookline Capital Management analyst L. Cann now aApril 9, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Holdings Lifted by Vanguard Group Inc.Vanguard Group Inc. increased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 4.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,925,213 shares of the company's stoApril 8, 2024 | finanznachrichten.deKymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingApril 8, 2024 | globenewswire.comKymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingMarch 29, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and six have assignMarch 28, 2024 | investing.comKymera Therapeutics Inc (KYMR)March 20, 2024 | finance.yahoo.comKYMR May 2024 30.000 callMarch 19, 2024 | finance.yahoo.comKYMR Aug 2024 20.000 putMarch 18, 2024 | bizjournals.comBiotech upgrades to new Watertown digs with triple the spaceMarch 16, 2024 | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth Sells 71,764 SharesMarch 14, 2024 | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Major Shareholder Venture Fund X. L.P. Atlas Sells 42,302 SharesMarch 13, 2024 | marketbeat.comGSA Capital Partners LLP Has $710,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)GSA Capital Partners LLP raised its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 141.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,088 sharMarch 8, 2024 | globenewswire.comKymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual MeetingMarch 7, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Fmr LLCFmr LLC raised its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 3.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 870,547 shares of the company's stock after acquiring an additional 32,335 shares du Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem (Ad)Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with … Find out details on these three critical Nvidia partners immediately. KYMR Media Mentions By Week KYMR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼0.410.87▲Average Medical News Sentiment KYMR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼103▲KYMR Articles Average Week Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ADMA News Today RXRX News Today NVAX News Today BEAM News Today CGON News Today SANA News Today VCEL News Today FUSN News Today INBX News Today IMCR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon’s New Device is About to Shock the WorldInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
